Type 2 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis-Reference-Cited by-同舟云学术

Type 2 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis

Published:2023-09 Issue:9 Volume:8 Page:829-836
ISSN:2468-1253
Container-title:The Lancet Gastroenterology & Hepatology
language:en
Short-container-title:The Lancet Gastroenterology & Hepatology

Author:

Huang Daniel Q,Noureddin Nabil,Ajmera Veeral,Amangurbanova Maral,Bettencourt Ricki,Truong Emily,Gidener Tolga,Siddiqi Harris,Majzoub Abdul M,Nayfeh Tarek,Tamaki Nobuharu,Izumi Namiki,Yoneda Masato,Nakajima Atsushi,Idilman Ramazan,Gumussoy Mesut,Oz Digdem Kuru,Erden Ayse,Allen Alina M,Noureddin Mazen,Loomba Rohit

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference47 articles.

1. Mechanisms and disease consequences of nonalcoholic fatty liver disease;Loomba;Cell,2021

2. Changes in the global burden of chronic liver diseases from 2012 to 2017: the growing impact of NAFLD;Paik;Hepatology,2020

3. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis;Riazi;Lancet Gastroenterol Hepatol,2022

4. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review;Younossi;Hepatology,2023

5. The global burden of metabolic disease: Data from 2000 to 2019;Chew;Cell Metab,2023

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Natural history and progression of metabolic dysfunction-associated steatotic liver disease;The Lancet Gastroenterology & Hepatology;2024-10

2. Editorial: Cardiometabolic criteria matters in MASLD;Alimentary Pharmacology & Therapeutics;2024-09-03

3. Editorial: Cardiometabolic criteria matters in MASLD—Authors' reply;Alimentary Pharmacology & Therapeutics;2024-09-03

4. Paradigm shift in steatotic liver disease (SLD): from NAFLD to MASLD;Kanzo;2024-09-01

5. Cardiometabolic criteria as predictors and treatment targets of liver‐related events and cardiovascular events in metabolic dysfunction‐associated steatotic liver disease;Alimentary Pharmacology & Therapeutics;2024-08-08